Prof Roden highlights the sessions dedicated to obesity and the metabolic syndrom held during the Liver meeting 2019 in Boston
So this year’s meeting of the AASLD in Boston specifically…
NASH Observatory
⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
Read MoreProf Roden highlights the sessions dedicated to obesity and the metabolic syndrom held during the Liver meeting 2019 in Boston
Unmasking a Stealth Killer: The Need for Increased Awareness of NASH.
The challenge with NAFLD and its variations is not merely lack of awareness of the disease, but also lack of a full understanding of its diagnosis, etiology, pathophysiology, and treatment throughout the community...
Pediatric Fatty Liver Disease: reports of NAFLD in patients as young as 2 years of age documented in an article by Dr Ajay Jain, Department of Pediatrics, saint louis university, in the USA.. have been
Pediatric Fatty Liver Disease: reports of NAFLD in patients as young as 2 years of age documented in an article by Dr Ajay Jain, Department of Pediatrics, saint louis university, in the USA..
Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers.
This liver meeting in 2019 is quite interesting for those…
Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.
Nonalcoholic fatty liver disease (NAFLD) has recently been recognized as an important etiology contributing to the increased incidence of hepatocellular carcinoma (HCC). The more aggressive form, nonalcoholic steatohepatitis (NASH)...
Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston.
I think there are going to be many take-home messages…
Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis
Nonalcoholic fatty liver disease (NAFLD) may occur in liver transplant recipients. This study aimed to investigate the prevalence and risk factors of NAFLD after liver transplantation in patients with NASH and cryptogenic cirrhosis...
Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting
Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting
Epidemiology of NAFLD and advanced fibrosis in the French general population: A population-based cohort study in 118, 664 subjects (NASH-CO study).
The aim of this study by L. Serfaty et al. was to assess the prevalence and risk factors of NAFLD and associated liver fibrosis in a French population-based cohort (118, 664 participants) by using using the Fatty Liver Index...
Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston
The liver meeting has been fantastic. There’s a lot of…
Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston
Discovers new clinical trials and new biomarkers
Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease
The human leukocyte antigen (HLA) genes may play a role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH). A. Karrar et al. aimed to assess the association...